1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > IMS Country Review 2016: Poland

IMS Country Review 2016: Poland

  • July 2016
  • -
  • IMS Health
  • -
  • 81 pages

IMS Country Review™ 2016 provides comprehensive qualitative insights into a specific pharmaceutical market as well as showing sales trends over the last 5 years. Sales performance is analysed in terms of major corporations, therapeutic classes, major products and new product activity.

Table Of Contents

IMS Country Review 2016: Poland
Table of Contents
SECTION 1: SYNOPSIS OF THE HEALTHCARE MARKET 5
MARKET TRENDS 5
HEALTHCARE PROVISION 5
PRESCRIBING POLICY 6
PRICING SYSTEM 7
REGULATORY ENVIRONMENT 7
INDUSTRY ENVIRONMENT 8
CHANNELS OF DISTRIBUTION 10
POLAND DATA COLLECTION 11
SECTION 2: COUNTRY SALES PERFORMANCE AND TRENDS 12
FIGURE 1: COUNTRY RANKING AMONGST 30 MARKETS WORLDWIDE 12
FIGURE 2: AUDITED MARKET TREND 13
FIGURE 3: LEADING 35 LOCAL COMPANIES 14
FIGURE 4: LEADING 35 CORPORATIONS 16
FIGURE 5: MARKET SHARE BY CORPORATE NATIONALITY 18
FIGURE 6: LEADING 15 THERAPEUTIC CLASSES (LEVEL 3) 2015 19
FIGURE 7: 15 FASTEST-GROWING THERAPEUTIC CLASSES (LEVEL 3) 2015 20
FIGURE 8-22: LEADING 15 THERAPEUTIC CLASS PROFILES 21
FIGURE 8: A2B ANTIULCERANTS 21
FIGURE 9: A10C HUMAN INSULIN+ANALOGUES 22
FIGURE 10: A10N DPP-IV INHIBITOR A-DIABS 23
FIGURE 11: B1B HEPARINS 24
FIGURE 12: B1E DIRECT THROMBIN INHIBIT. 25
FIGURE 13: B1F DIRECT FACTOR XA INHIBS 26
FIGURE 14: C7A B-BLOCKING AGENTS,PLAIN 27
FIGURE 15: C10A CHOLESTandTRIGLY.REGULATOR 28
FIGURE 16: G3G GONADOTROPHINS 29
FIGURE 17: J5B ANTIVIRALS EXCL ANTI-HIV 30
FIGURE 18: L1G MAB ANTINEOPLASTICS 31
FIGURE 19: L1H PROTEIN KINASE INH A-NEO 32
FIGURE 20: L1X ALL OTH. ANTINEOPLASTICS 33
FIGURE 21: M1C SPEC ANTIRHEUMATIC AGENT 34
FIGURE 22: N2B NON-NARCOTIC ANALGESICS 35
FIGURE 23: LEADING 40 PRODUCTS 36
FIGURE 24: LEADING 40 NEW PRODUCTS 38
FIGURE 25: LEADING 15 PRODUCT FORMS 40
FIGURE 26: FASTEST GROWING 40 PRODUCTS SALES TRENDS 41
SECTION 3: APPENDICES 43
APPENDIX 1: AUDITED UNIVERSE 43
APPENDIX 2: COUNTRY SPECIFIC ALERTS 44
APPENDIX 3: MEASURE INDEX 47
APPENDIX 4: SALES DATA MEASURES 49
APPENDIX 5: *LATEST FACTORS 51
APPENDIX 6: QUARTERLY US$ EXCHANGE RATES BY COUNTRY 55
APPENDIX 7: CORPORATIONS 57
APPENDIX 8: PRODUCT NAMES 58
APPENDIX 9: THERAPIES 60
APPENDIX 10: EPHMRA ANATOMICAL THERAPEUTIC CLASSIFICATION 61

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.